These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 29369972

  • 1. mTOR Inhibition and Kidney Diseases.
    Ma MKM, Yung S, Chan TM.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
    [Abstract] [Full Text] [Related]

  • 2. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract] [Full Text] [Related]

  • 3. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.
    Paoletti E.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S41-S43. PubMed ID: 28230637
    [Abstract] [Full Text] [Related]

  • 4. mTOR Inhibition and Clinical Transplantation: Heart.
    Zuckermann A, Osorio-Jaramillo E, Aliabadi-Zuckermann AZ.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
    [Abstract] [Full Text] [Related]

  • 5. mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.
    Berney T, Andres A, Toso C, Majno P, Squifflet JP.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S30-S31. PubMed ID: 28230643
    [Abstract] [Full Text] [Related]

  • 6. mTOR Inhibition and Clinical Transplantation: Liver.
    Nashan B.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
    [Abstract] [Full Text] [Related]

  • 7. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
    Tedesco Silva H.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
    [No Abstract] [Full Text] [Related]

  • 8. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F.
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [Abstract] [Full Text] [Related]

  • 9. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP, Kistler AD, Serra AL.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [Abstract] [Full Text] [Related]

  • 10. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J, Bridson JM, Sharma A, Halawa A.
    Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The pros and the cons of mTOR inhibitors in kidney transplantation.
    Ponticelli C.
    Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
    Fernandes-Silva G, Ivani de Paula M, Rangel ÉB.
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ, Paul E.
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. mTOR inhibitors in pediatric kidney transplantation.
    Pape L, Ahlenstiel T.
    Pediatr Nephrol; 2014 Jul; 29(7):1119-29. PubMed ID: 23740036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.